Table 2.
Baseline clinical and biochemical characteristics of 203 CKD5 patients according to tertiles of a body shape index (ABSI).
| All | Low tertile | Mid + high tertile | Value of p | |
|---|---|---|---|---|
| N = 203 | N = 67 | N = 136 | ||
| ABSI | 0.9 (0.8–0.9) | 0.8 (0.8–0.8) | 0.9 (0.9–0.9) | <0.001 |
| Age, years | 56.0 (43.5–66.8) | 47.0 (32.0–58.0) | 60.5 (49.0–67.9) | <0.001 |
| Male sex, n (%) | 138 (68.0%) | 39 (58.2%) | 99 (72.8%) | <0.05 |
| Diabetes mellitus, n (%) | 34 (17.1%) | 6 (9.2%) | 28 (20.9%) | <0.05 |
| CVD, n (%) | 43 (21.5%) | 12 (18.5%) | 31 (23.0%) | ns |
| FRS% | 13.6 (5.6–27.2) | 7.4 (3.0–16.2) | 17.1 (7.9–29.2) | <0.001 |
| Systolic BP, mmHg | 143 (130–153) | 149 (130–156) | 140 (129–151) | ns |
| Diastolic BP, mmHg | 86 (76–93) | 86 (79–95) | 85 (76–92) | ns |
| Malnutrition (SGA) | 77 (38.9%) | 28 (42.4%) | 49 (37.1%) | ns |
| Height, cm | 173 (165–180) | 171 (163–180) | 174 (167–180) | ns |
| Weight, kg | 74.0 (65.0–84.3) | 74.0 (61.0–84.1) | 74.3 (67.0–84.4) | ns |
| BMI, kg/m2 | 24.6 (22.2–27.5) | 23.5 (21.3–26.9) | 24.7 (22.5–27.7) | ns |
| Handgrip strength, % (n = 175) | 83.7 (66.3–100.0) | 93.0 (79.1–107.0) | 76.7 (63.0–95.3) | <0.001 |
| Waist circumference (cm) | 95.0 (86.5–104.5) | 87.5 (79.0–94.0) | 99.0 (93.0–107.0) | <0.001 |
| Hemoglobin, g/L | 114 (104–121) | 114 (102–122) | 114 (105–121) | ns |
| Albumin, g/L | 34.0 (31.0–37.0) | 34.0 (31.0–37.0) | 35.0 (31.0–37.0) | ns |
| Triglyceride, mmol/L | 1.5 (1.2–2.2) | 1.5 (1.2–1.9) | 1.5 (1.1–2.3) | ns |
| Total cholesterol, mmol/L | 4.3 (3.6–5.2) | 4.8 (3.9–5.4) | 4.3 (3.5–5.0) | <0.01 |
| HDL-cholesterol, mmol/L | 1.2 (1.0–1.6) | 1.5 (1.2–1.8) | 1.2 (1.0–1.4) | <0.001 |
| LDL-cholesterol, mmol/L | 2.7 (2.0–3.4) | 2.8 (2.2–3.6) | 2.6 (1.9–3.3) | ns |
| Calcium, mmol/L | 2.3 (2.1–2.4) | 2.3 (2.2–2.4) | 2.3 (2.1–2.4) | ns |
| Phosphate, mmol/L | 1.8 (1.5–2.1) | 1.8 (1.6–2.2) | 1.8 (1.5–2.1) | ns |
| iPTH, ng/L | 274 (190–443) | 245 (141–375) | 292 (203–450) | ns |
| hsCRP, mg/L | 1.5 (0.8–4.8) | 1.1 (0.6–1.9) | 2.4 (0.9–6.8) | <0.001 |
| IL-6, pg./ml (n = 126) | 4.0 (2.1–7.8) | 2.6 (0.5–4.5) | 5.1 (2.3–8.8) | <0.001 |
| ABSI | 1.3 (1.3–1.4) | 1.2 (1.2–1.3) | 1.4 (1.3–1.4) | <0.001 |
| AIP | 0.2 (−0.2–0.6) | 0.1 (−0.3–0.4) | 0.3 (−0.1–0.8) | <0.01 |
| CAC Score, AU | 133.9 (0.0–1,224.9) | 7.9 (0.0–244.2) | 329.5 (6.6–1,624.7) | <0.001 |
| AVC score, AU | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.0 (0.0–36.5) | <0.001 |
| Beta-blocker (n = 197) | 128 (65.0%) | 39 (60.0%) | 89 (67.4%) | ns |
| Ca-blocker (n = 174) | 91 (52.3%) | 32 (59.3%) | 59 (49.2%) | ns |
| ACEi/ARB (n = 72) | 54 (75%) | 16 (80%) | 38 (73%) | ns |
| Statin user (n = 198) | 84 (42.4%) | 20 (30.8%) | 64 (48.1%) | <0.05 |
Data are presented as median (IQR, interquartile range) for continuous measures, and n (%) for categorical measures.
AVC, aortic valve calcium; ABSI, a body shape index; AIP, atherogenic index of plasma; CI, conicity index; CVD, cardiovascular disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; FRS, Framingham CVD risk score; PEW, protein-energy wasting; SGA, subjective global assessment; BMI, body mass index; %HGS, hand grip strength, converted to % of sex-matched healthy controls; HDL, high-density lipoprotein; LDL, low-density lipoprotein; iPTH, intact parathyroid hormone; hsCRP, high sensitivity C-reactive protein; IL-6, interleukin-6; AU, Agatston units; CAC, coronary artery calcium; ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers.